Anna-Maria Hoffmann-Vold: building bridges in systemic sclerosis.

Abstract

“A lot of my focus is on building the bridge between basic science and clinical science,” says Anna-Maria Hoffmann-Vold, rheumatologist at Oslo University Hospital in Norway. Hoffmann-Vold leads research in inflammatory and fibrotic diseases and also runs a clinic for patients with systemic sclerosis and connective tissue disease-associated interstitial lung disease, noting the integral connection between the two. “Without basic evidence, what we do in the clinic is not really evidence-based. And on the other hand, if you develop anything in the lab, it doesn't help if it's not implemented into the clinics,” she says. Collaborative working is also a priority, uniting people who are “often in totally different worlds” but are travelling down the same road. With experience and persistence, Hoffmann-Vold builds the bridge piece by piece. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statementsThrough a robust modified Delphi process developed by a diverse panel of experts, the first evidence-based consensus statements were established on guidance for the identification and medical management of systemic sclerosis-associated ILD. Full-Text PDF